Novocure Limited · NASDAQ:NVCR
Novocure — Corporate Update (December 2015)
17 slides from Novocure's corporate update, Dec 15, 2015
Slide 1: EF-14 Publication in JAMA
EF-14 Publication in JAMA December 15, 2015 Exhibit 99.3
Slide 2: Introduction
Introduction Ashley Cordova Senior Director, Investor Relations and Treasury EF-14 Publication in JAMA
Slide 3: Forward Looking Statements
Forward Looking Statements Discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control, includi
Slide 4: Opening Remarks
Opening Remarks Bill Doyle Executive Chairman EF-14 Publication in JAMA
Slide 5: EF-14 Publication on December 15
EF-14 Publication on December 15 EF-14 Publication in JAMA Copyright © 2015 American Medical Association. All Rights Reserved.
Slide 6: EF-14 Publication Review
EF-14 Publication Review Eilon Kirson Chief Science Officer and Head of Research and Development EF-14 Publication in JAMA
Slide 7: Importance of EF-14 Data
Importance of EF-14 Data GBM is the most common and aggressive form of primary brain cancer Most patients die within 1 to 2 years of diagnosis Tumor Treating Fields, or TTFields, are an antimitotic treatment that selectively disrupts cell division by delivering low-intensity, intermediate-frequency,
Slide 8: EF-14 Trial Design
EF-14 Trial Design A prospective, multicenter trial of TTFields together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM Pre-specified interim analysis 18 months after enrollment of the 315th patient Endpoints: Primary endpoint – PFS (intent to treat) Secondary
Slide 9: EF-14 Trial Results
EF-14 Trial Results Progression-Free Survival Overall Survival Median increase in overall survival of 4.9 months from 15.6 to 20.5 months Hazard ratio, 0.64; P = .004 Median increase in PFS of 3.1 months from 4.0 to 7.1 months Hazard ratio, 0.62; P = .001 EF-14 Publication in JAMA
Slide 10: Recruitment and Patient Inclusions
Recruitment and Patient Inclusions 1019 patients signed informed consent and were screened 695 patients randomized 2:1 315 patients competed a minimum of 18 months follow-up and were included in interim primary analysis Per protocol analysis excluded, among others, 11 patients who crossed over from
Slide 11: Patient Characteristics
Patient Characteristics Baseline characteristics All Patients n=315 TTFields + temozolomide n=210 Temozolomide alone n=105 Median age (range) 57 (20-83) 57 (20-83) 58 (21-80) Gender, n (%) Male 207 (66) 140 (67) 67 (64) Female 108 (34) 70 (33) 38 (36) Median KPS (range) 90 (60-100) 90 (60-100) 90 (7
Slide 12: Supplemental Online Content
Supplemental Online Content Multiple imputation analyses on the primary endpoint to test sensitivity to possible bias using informative and interval censoring Consider a change in progression timing within the inter-MRI interval Significance is maintained in all scenarios Progression-free survival r
Slide 13: JAMA Conclusion
JAMA Conclusion Conclusions and Relevance In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival. EF-14 Publication in JAMA Co
Slide 14: Concluding Remarks
Concluding Remarks Bill Doyle Executive Chairman EF-14 Publication in JAMA
Slide 15: 2016 Commercial Catalysts
ü ü FDA approval Allows sales force to promote EF-14 data Doubles the potential market size Increases the average treatment duration 2016 Commercial Catalysts EF-14 publication Escalates visibility of EF-14 data in the scientific community Provides peer-reviewed validation of EF-14 data Guidelines u
Slide 16: Multiple Ongoing Clinical Trials
Multiple Ongoing Clinical Trials EF-14 Publication in JAMA
Slide 17: Q&A Session
Q&A Session EF-14 Publication in JAMA